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Abstract It has been suggested that the C-terminal domain of
Bcl-2 family members may contain a signal anchor sequence that
targets these proteins to the mitochondrial outer membrane. We
have investigated the consequence of deleting this domain upon
cytochrome c release in yeast strains that coexpress truncated
forms of Bax (i.e. Baxv) and Bcl-xL (i.e. Bcl-xLv). We find that
(i) Baxv is as efficient as full-length Bax in promoting
cytochrome c release, but Bcl-xLv has remarkably reduced
rescuing ability compared to full-length Bcl-xL ; (ii) full-length
Bcl-xL protein acts by relocalizing Bax from the mitochondrial
fraction to the soluble cytosolic fraction; (iii) Bax undergoes N-
terminal cleavage when expressed in yeast, which is prevented by
coexpression of Bcl-xL, suggesting that Bcl-xL may mask the
cleavage site of Bax through a direct physical interaction of the
two proteins.
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1. Introduction
Apoptosis has been termed ‘programmed cell death’, which
occurs under physiological circumstances. It aims to remove
cells during development and regulation of tissue homeostasis
in organs. Certain features of this program depend on the cell
type, but some general characteristics are displayed by most
mammalian cells. Whatever the method of induction of apop-
tosis, cytosolic signal transduction pathways are always re-
cruited that end up in the nucleus where anti-apoptotic genes
are switched o¡ and pro-apoptotic genes are switched on. This
confers the apoptotic morphology on the cells which can be
monitored via nuclear fragmentation, chromatin condensa-
tion, cell shrinkage, membrane blebbing and budding of apop-
totic bodies.
The Bcl-2 family of proteins has been identi¢ed as regula-
tors of apoptosis, some being pro-apoptotic (Bax, Bad, Bcl-
xS) while others are anti-apoptotic (Bcl-2, Bcl-xL). Members
of this family have been identi¢ed through sequence compar-
isons with Bcl-2. Most family members contain four con-
served domains (BH1^4; note that Bax does not contain the
BH4 domain (Fig. 2)). Some of them also have a C-terminal
hydrophobic K-helical domain that has been postulated to act
as a membrane anchor (Fig. 2).
Two-hybrid and coimmunoprecipitation experiments have
shown that Bcl-2 family members have the ability to homo-
and heterodimerize. The BH3 domain is critical for these in-
teractions but the C-terminal domain seems to be dispensable
[1]. It has been proposed that the ratio between the pro- and
the anti-apoptotic proteins rules the destiny of the cell. In
addition, nuclear magnetic resonance and X-ray crystallo-
graphic analyses have highlighted some structural similarities
to bacterial toxins and pore-forming proteins, suggesting that
proteins of the Bcl-2 family may insert into membranes and
act as ionic and/or protein channels [2,3]. Consistent with
membrane localization, immuno£uorescence data and immu-
nohistostaining show that Bcl-2 family proteins are associated
with the outer nuclear membrane, the endoplasmic reticulum
and the outer mitochondrial membrane.
The possible pathways in which Bcl-2 family members act
as regulators of apoptosis are still not fully elucidated. How-
ever, it is certain that speci¢c mitochondrial events occur in
response to induction of apoptosis. It has been observed that
Bax expression triggers cytochrome c release from the mito-
chondrial intermembrane space to the cytosol [4]. The precise
mechanism of this release is unknown. It has been proposed
that the channel activity of the Bax protein is countered by a
corresponding Bcl-xL channel activity and this leads to a dys-
regulation of the ionic composition in the mitochondrial in-
termembrane space. The result is that the outer mitochondrial
membrane is disrupted and thereby cytochrome c is released
[5]. Another hypothesis envisages Bcl-2 as a negative regulator
of a mitochondrial megachannel, the permeability transition
pore (PTP). It is thought that heterodimerization with Bax
nulli¢es Bcl-2 function and causes the opening of the PTP
with subsequent mitochondrial swelling that leads to disrup-
tion of the outer mitochondrial membrane [6,7].
Although yeast cells do not express any Bcl-2-related pro-
teins, it has been shown that at least one functional aspect of
Bax and Bcl-xL is conserved in yeast cells. Human Bax causes
cytochrome c release and coexpression of Bcl-xL suppresses
this phenomenon [8]. In this communication, we have at-
tempted to explore the role of the C-terminal domain in the
Bcl-2 family of proteins, using yeast as a model system. The
C-terminal sequence consists of a hydrophobic K-helix that
should allow docking of proteins into host membranes. It is
not clear from the published literature if the truncated forms
of Bax and Bcl-xL (i.e. Baxv and Bcl-xLv, respectively) retain
the same function and dimerization ability of the full-length
molecules. Moreover, it is not known if the truncated mole-
cules associate at all with the mitochondria.
In fact, contradictory results have been obtained for Baxv
and Bcl-2v using similar cellular systems. On the one hand,
Zha et al. [9] found that Baxv retains its toxicity and mito-
chondrial localization only in mammalian cells but not in
yeast. The explanation was that in mammals, endogenous
Bax in the outer mitochondrial membrane allows for interac-
tions with Baxv, whereas this cannot happen in yeast since no
endogenous Bax exists in this simple eukaryote. These results
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suggested that the targeting sequence in Bcl-2-like proteins
may not be required if an endogenous membrane-bound pro-
tein allows for the interaction with an anchorless Bcl-2 homo-
log. However, when an endogenous regulator of cell death is
absent, the membrane anchor of a pro-apoptotic protein
would be essential for mitochondrial localization and imposi-
tion of cell death. In contrast to these ¢ndings, Nguyen et al.
[10] have found that Bcl-2v is no longer targeted to the mi-
tochondrial outer membrane in mammalian cells even in the
presence of membrane-bound endogenous Bcl-2. But it must
be said that the authors have not investigated the rescuing
ability of the Bcl-2v protein [10].
Amidst these con£icting observations, we have tried to ¢nd
out if the anchorless Bcl-2-like proteins are indeed targeted to
the mitochondria or, in other words, if the C-terminal domain
has any function in regulating cell death.
2. Materials and methods
2.1. Yeast strains
The strains used in this study are summarized in Table 1.
Human bax and baxv172^192 genes were chemically synthesized
with yeast codon bias, to encode K-isoform of both proteins. The
genes were placed under the control of the GAL10 promoter and
fused to a fragment containing the SUC2 transcription terminator
with a 5P DNA sequence encoding the c-myc epitope EQKLI-
SEEDLNG [11]. These constructions were integrated at the LEU2
locus of the wild type strain HT444.
The Bax and Baxv expressing strains thus obtained were trans-
formed with a pDP83 plasmid (a CEN-14, YCp vector with URA3
as yeast selection marker) that carries either bcl-xL or bcl-xLv human
genes under the control of the GAL10 promoter.
2.2. Cell fractionation
Cell culture conditions, spheroplast preparation and mitochondrion
isolation have been fully described previously [8]. Besides, post-mito-
chondrial supernatants were centrifuged ¢rst at 130 000Ug for 35 min,
which allows separation of the microsomal fraction (pellet) and cyto-
solic fraction (supernatant).
2.3. Cytochrome c detection
Cytochrome c release was measured by the spectrophotometric
method on permeabilized spheroplasts, where the expression of
Bcl-2 family proteins had been induced for 3 h by addition of 1%
galactose in the culture medium.
Spectra were recorded in an Aminco DW2000 double-beam spec-
trophotometer, on dithionite-reduced versus H2O2-oxidized samples.
2.4. Western blotting
In each fraction, protein concentrations were estimated with the
Lowry method. Samples were solubilized in 2% SDS at 65‡C for 15
min, separated on 12.5% SDS-polyacrylamide gel, and transferred to
nitrocellulose membranes (Problott, Applied Biosystems). Membranes
were blocked with 1% BSA in PBS/0.1% Tween 20 for 30 min, and
subsequently blotted with primary monoclonal anti-c-myc antibodies
(Santa Cruz Biotechnology) for 1 h. Then, the membranes were blot-
ted with horseradish peroxidase-linked secondary antibodies (Immuno
Pure, Pierce) for another hour. The protein bands were visualized with
a chemiluminescence assay system (ECL, Amersham).
3. Results and discussion
3.1. Cytochrome c release in strains expressing Bax or Baxv,
and in strains that coexpress these proteins along with
Bcl-xL or Bcl-xLv
Permeabilized spheroplasts were prepared from yeast
strains, referred to as ‘Bax’ and ‘Baxv’ (i.e. strains that ex-
press full-length human Bax or the truncated Bax without its
putative C-terminal transmembrane domain, in galactose-con-
taining medium), to investigate if both forms of the pro-apop-
totic protein are able to trigger cytochrome c release from the
mitochondrial intermembrane space to the cytosol. Moreover,
since it has been established that anti-apoptotic Bcl-xL can
reverse Bax e¡ects in yeast as well as in mammalian cells,
full-length and the truncated Bcl-xL molecules (i.e. Bcl-xLv
that lacks the C-terminal transmembrane domain in Bcl-xL)
were coexpressed with Bax and Baxv in the ‘Bax’ and ‘Baxv’
strains. We were curious if Bcl-xLv would be as e⁄cient as
full-length Bcl-xL in rescuing cells from the e¡ects of Bax and
Baxv.
We con¢rmed that about 60% of total cytochrome c was
released from mitochondria after a 3 h induction of Bax ex-
pression in galactose-containing medium (Fig. 1) [8]. Under
identical experimental conditions, Baxv was as e⁄cient as
full-length Bax in promoting cytochrome c release (Fig. 1).
These results di¡er from those reported by Zha et al. [9].
The di¡erences may be due to the use of chimeric proteins.
The constructs were made by fusing both Bax and Baxv to
the LexA DNA-binding domain (DBD) or the B42 transacti-
vation domain (TA). It is possible that the expressed Baxv
fusion protein in particular [9] undergoes certain conforma-
tional changes so that the toxicity of Baxv in yeast is no
longer manifested. Moreover, if the C-terminal truncation in
Bax really abrogates mitochondrial targeting, as proposed by
Zha et al. [9], a possible explanation for our Baxv-mediated
cytochrome c release could be that the truncated molecule
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Table 1
Yeast strains
HT444 MATa, leu2, his4, ura3, lys2
Bax MATa, his4, leu2, lys2, ura3, LEU2 = gal10p-bax
Baxv MATa, his4, leu2, lys2, ura3, LEU2 = gal10p-baxv
Bax/Bcl-xL MATa, his4, leu2, lys2, ura3, LEU2 = gal10-bax,
pDP83A/gal10p-bcl-xL (URA3)
Bax/Bcl-xLv MATa, his4, leu2, lys2, ura3, LEU2 = gal10-bax,
pDP83A/gal10p-bcl-xLv (URA3)
Baxv/Bcl-xLv MATa, his4, leu2, lys2, ura3, LEU2 = gal10-baxv,
pDP83A/gal10p-bcl-xLv (URA3)
Baxv/Bcl-xL MATa, his4, leu2, lys2, ura3, LEU2 = gal10-baxv,
pDP83A/gal10p-bcl-xL (URA3)
Fig. 1. Comparison of the ability of Bax and Baxv to promote cy-
tochrome c release, and the e⁄ciency of Bcl-xL and Bcl-xLv in pre-
venting this. Cells were grown in YP liquid medium supplemented
with 2% lactate, until late-exponential phase. Protein expression was
induced for 3 h by adding 1% galactose. Spheroplasts were prepared
and were permeabilized with nystatin as described in Section 2.
After centrifugation, cytochrome c was measured in pellets and
supernatants. Results present the percent of cytochrome c found in
the supernatant.
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triggers the event through a mechanism di¡erent from that
used by full-length Bax which is found mostly in the outer
mitochondrial membrane.
We have also con¢rmed that coexpression of full-length
anti-apoptotic Bcl-xL prevents cytochrome c release triggered
by full-length Bax (Fig. 1) [8]. But we found that Bcl-xLv only
partially reverses the e¡ects of Bax. Only about 25% of total
cytochrome c is found in the supernatant of ‘Bax/Bcl-xLv’
cells (Fig. 1). From this observation, one can conclude that
truncation of the putative C-terminal transmembrane domain
partially impairs the protective function of Bcl-xL. Addition-
ally, we have observed that neither Bcl-xL nor Bcl-xLv was
able to impede cytochrome c release triggered by truncated
pro-apoptotic Baxv (Fig. 1). This raises a pertinent question
regarding the true role of the C-terminal domain in interac-
tions between members of the Bcl-2 family. Two-hybrid ex-
periments indicate that the domain may be redundant for
homo- or heterodimerization between members of the Bcl-2
family [1]. However, it is possible that the structural altera-
tions induced by fusing genes with lexA-DBD and B42-TA
domains may have concealed the real importance of the C-
terminal domain. Our results seem to suggest that the C-ter-
minal domain has a crucial role to play in the interactions
between Bax and Bcl-xL.
3.2. Bax and Baxv localization
Since our results relating to Baxv do not agree with pre-
vious ¢ndings, we decided to investigate if Baxv is found
associated with the mitochondria after cell fractionation. We
therefore isolated spheroplasts and mitochondria from Bax
and Baxv strains after a 3-h expression, and separated the
solubilized proteins by SDS-PAGE (Fig. 2). Expression of
V21 kDa Bax and V18 kDa Baxv proteins was detected
in lanes a and c, where proteins from whole spheroplasts
were loaded. This indicates that both proteins are expressed
and that immunodetection is speci¢c. These bands were also
found in mitochondrial fractions (lanes b and d). Hence, it
can be inferred that both Bax and Baxv are associated with
mitochondria. This implies that the C-terminal domain of Bax
is not necessary for targeting or for its docking into the outer
mitochondrial membrane and it supports our earlier observa-
tion that Bax and Baxv are indistinguishable in their cyto-
chrome c-releasing function.
Further analysis of the immunoblot reveals another unex-
pected phenomenon. Both Bax and Baxv appear to have
undergone cleavage at their N-terminal ends, but only in the
mitochondrial fractions. Cleavage of Bax and Baxv in mito-
chondria yields a V17 kDa and a V14 kDa protein, respec-
tively (see lanes b and d, lower bands). Moreover, cleavage
was also observed in microsomal fractions (Fig. 3, lane e). To
the best of our knowledge, such a phenomenon has never been
observed in mammalian cells, so we can draw no conclusions
about its true physiological relevance. However, it would
be interesting to know if the mitochondrial cleavage products
of Bax and Baxv are also able to promote release of cyto-
chrome c. Further experiments will be necessary to elaborate
on this point.
In order to obtain an insight into the mechanism by which
Bcl-xL prevents Bax-induced cytochrome c release, we inves-
tigated Bax localization after fractionation of cells that ex-
press only Bax or coexpress both Bax and Bcl-xL. Full-length
Bax was detected in spheroplasts (Fig. 3, lanes a and b),
showing that Bcl-xL does not alter the levels of Bax expres-
sion. Mitochondrial fractions and microsomes contained not
only the V21 kDa band, but also the V17 kDa one. But
total amounts of Bax (i.e. the full-length 21 kDa Bax plus the
17 kDa cleavage product) are di¡erent in the mitochondrial
fractions of ‘Bax’ and ‘Bax/Bcl-xL’ cells (Fig. 3, compare the
summation of intensities of the two bands in lanes c and d).
This may suggest that coexpression of Bcl-xL decreases the
levels of Bax targeted to the mitochondria. Indeed, Bax pro-
teins that were no longer found in mitochondrial membrane
fractions of ‘Bax/Bcl-xL’ cells were detected in the supernatant
(Fig. 3, lane h). Interestingly, the soluble form of Bax is not
seen in the absence of Bcl-xL (Fig. 3, lane g). All these data
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Fig. 3. E¡ects of Bcl-xL on Bax localization. Cells were grown on
YP medium supplemented with 2% lactate until 5 OD550nm units.
Then Bax and Bcl-xL expression was induced for 3 h by adding 1%
galactose. Proteins were measured by the Lowry method, and sam-
ples were analyzed by SDS-PAGE and Western blotting. Bax was
immunodetected as described in Section 2. Lanes a and b, 150 Wg
of total protein. Lanes c, d, e, and f, 100 Wg of total protein. Lanes
g and h: 50 Wg of total protein.
Fig. 2. Cleavage of Bax and Baxv. Cells were grown in YP liquid
medium supplemented with 2% lactate, until late-exponential phase.
Then Bax or Baxv expression was induced for 3 h by adding 1%
galactose. For each fraction, 200 Wg of proteins were separated on
SDS-PAGE. Bax and Baxv were immunodetected as described in
Section 2. Lane a, Bax in spheroplasts. Lane b, Baxv in sphero-
plasts. Lane c, Bax in mitochondrial fraction. Lane d, Baxv in mi-
tochondrial fraction.
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seem to indicate that expression of Bcl-xL alters the intracel-
lular localization of Bax.
It should also be noticed that there are dramatic di¡erences
in the levels of the cleaved 17 kDa form of Bax in mitochon-
drial/microsomal fractions obtained from ‘Bax/Bcl-xL’ cells
and ‘Bax’ cells. In ‘Bax/Bcl-xL’ cells, the cleaved form is neg-
ligible. Moreover, the 17 kDa cleaved product of Bax is not
seen in supernatants of ‘Bax’ cells. Since it is assumed that
Bax and Bcl-xL heterodimerize to negate each other’s e¡ects,
it could be speculated that Bcl-xL interacts with Bax in such a
way that its cleavage site remains hidden.
4. Conclusion
Targeting of proteins to mitochondria usually implies that
an N-terminal positively charged K-helical signal sequence in-
serts into the outer mitochondrial membrane. This insertion is
v8-independent, ATP-dependent and temperature-sensitive
[12]. Previous reports have claimed that the C-terminal puta-
tive transmembrane domain of the Bcl-2 family of proteins
(such as Bax or Bcl-2) can act as a signal anchor sequence.
This is based on the assumption that the proteins localize to
mitochondrial membranes. In this paper, we have demon-
strated that, at least for Bax, deletion of its C-terminal do-
main does not impair its association with mitochondrial sub-
cellular fractions, nor does it impede the release of
cytochrome c from the mitochondria to the cytosol. Thus,
Baxv retains the same toxicity as full-length Bax in yeast cells.
However, results obtained from experiments that use Bcl-xLv
do not allow an analogous conclusion. This is because Bcl-
xLv loses most of its rescuing ability, suggesting that the C-
terminal domain of Bcl-xL is important for its protective func-
tion during Bax-induced cytochrome c release. Full-length
Bcl-xL which annuls this release can e⁄ciently perform this
function by relocalizing Bax to the cytosol. It has yet to be
determined if Bcl-xL establishes direct physical contacts with
Bax. A strong argument in favor of this idea is our observa-
tion that Bax is no longer found to be cleaved at its N-termi-
nal side when Bcl-xL is coexpressed.
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